Moleculin(US:MBRX)2026-03-19 12:35Clinical Trial Results - Moleculin reported a preliminary blinded complete remission composite (CRc) rate of 40% in the first 30 subjects treated in the MIRACLE trial, consisting of a 30% complete remission (CR) rate and a 10% complete remission with partial hematological recovery (CRh) rate[5]. - The MIRACLE trial is expected to unblind data for 45 subjects in mid-2026, with a total of 222 additional subjects to be randomized in Part B of the trial[9][7]. - Approximately 35% of subjects treated to date in the MIRACLE trial are relapsed or refractory from a venetoclax regimen, indicating a challenging patient population[5]. Financial Performance - The company reported a net loss of $33.6 million for the year ended December 31, 2025, compared to a net loss of $26.0 million in 2024, with a net loss per common share of $28.42[23]. - Research and development (R&D) expenses for the year ended December 31, 2025, were $15.9 million, a decrease of $1.8 million from $17.7 million in 2024, primarily due to reduced sponsored research activities[13]. - General and administrative (G&A) expenses increased to $9.2 million in 2025 from $8.9 million in 2024, attributed to higher regulatory, legal, consulting, and investor relations expenses[14]. Assets and Liabilities - As of December 31, 2025, the company had cash and cash equivalents of $8.9 million, with total current assets amounting to $9.7 million, an increase from $5.2 million in 2024[15][23]. - Moleculin's total assets as of December 31, 2025, were $22.1 million, up from $16.9 million in 2024, while total liabilities increased to $7.1 million from $5.7 million[23]. Future Plans - The company anticipates starting a Phase 1B/2 study of Annamycin in third-line pancreatic cancer in the second half of 2026[9][10]. - The company has entered a new research collaboration focused on glioblastoma multiforme (GBM) to evaluate intra-arterial delivery of Annamycin in preclinical models[6].